-
Valeant's High Debt Load Puts Q4 Focus On EBITDA Guidance
Monday, February 27, 2017 - 10:12am | 303Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is scheduled to report its fourth-quarter results Tuesday. “Given Valeant’s elevated leverage, lower growth, and higher risk profile, we believe that a discount to the specialty pharma peer group is warranted,” Canaccord Genuity’s...
-
Criminal Charges Against Former Valeant Exec 'Not Pertinent But Underscores Cautious Outlook'
Friday, November 18, 2016 - 1:45pm | 282Read More...Federal prosecutors in the state of New York charged former Valeant Pharmaceuticals Intl Inc (NYSE: VRX) executive Gary Tanner for alleged colluding with Andrew Davenport, who was Philidor Rx's CEO. It was further alleged that $40 million was routed toward Davenport through various entities, and...
-
The FDA Showing Valeant Some Love With Recent Drug Approvals
Wednesday, July 20, 2016 - 1:58pm | 292Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s stock got a boost on Wednesday after the U.S. Food and Drug Administration (FDA) approved the company's RELISTOR Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. Valeant said in a press release that it...
-
Canaccord Sees More Bumps In The Road Ahead For Valeant
Friday, June 3, 2016 - 8:34am | 256Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is scheduled to report its 1Q financial results on June 7. Canaccord Genuity’s Neil Maruoka maintained a Hold rating for the company, with a price target of $40. The analyst commented that the company continues to face challenges and its full-...
-
Some On Wall Street Still Back Valeant
Tuesday, March 15, 2016 - 11:51am | 558Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plunged 40 percent and touched a new 52-week low after the company reported a loss for its fourth quarter and slashed its outlook. The company cited incremental headwinds in Ophthalmology Rx, as well as the Commonwealth and Western Europe businesses...
-
Valeant's New-Old CEO: What To Know
Wednesday, March 2, 2016 - 3:33pm | 350Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s Chief Executive Michael Pearson, who just got back from a two-month sick leave, has his job cut out. The Canadian pharma company is facing several issues including delayed filing of its 10-K, a potential earnings restatement, withdrawn 2016...
-
Canaccord Cuts Valeant To $75, Says 'Silence Is Deafening'
Wednesday, March 2, 2016 - 9:40am | 174Read More...Canaccord Genuity's Neil Maruoka downgraded the rating for Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from Buy to Hold, while reducing the price target from $125 to $75. He said that lack of transparency and clear communication by the company had eroded investor confidence. "The delayed filing...
-
Valeant Pharmaceuticals Is Kicking Butt, Says Canaccord Genuity
Tuesday, February 24, 2015 - 5:00pm | 256Read More...In a report published Monday, Canaccord Genuity analyst Neil Maruoka commented that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is "firing on all cylinders." Valeant On Fire Maruoka noted the company's strong fourth-quarter report that showed a "robust" base business...
